close
References
  1. Feldman SR, Cox LS, Strowd LC, et al. The challenge of managing atopic dermatitis in the United States. Am Health Drug Benefits. 2019;12(2):83-93.
  2. Drucker AM, Wang AR, Li W-Q, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
  3. Hamilton CE, Craiglow BG. JAK inhibitors for the treatment of pediatric alopecia areata. J Investig Dermatol Symp Proc. 2020;20(1):S31-S36.
  4. Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc. 2020;20(1):S62-S68.
  5. Petukhova L, Christiano AM. The genetic architecture of alopecia areata. J Investig Dermatol Symp Proc. 2013;16(1):S16-S22.
  6. Huang KP, Mullangi S, Guo Y, Qureshi AA. Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol. 2013;149(7):789-794.
  7. Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2);144-151.
  8. Wei W, Anderson P, Gadkari A, et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. J Dermatol. 2018;45(2):150-157.
  9. Pourang A, Mesinkovska NA. New and emerging therapies for alopecia areata. Drugs. 2020;80(7):635-646.
  10. Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83(1):123-130.
  11. Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin disease. Front Immunol. 2019;10:2342.
  12. Guttman-Yassky E, Waldman A, Ahluwalia J, Ong PY, Eichenfield LF. Atopic dermatitis: pathogenesis. Semin Cutan Med Surg. 2017;36(3):100-103.
  13. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109-1122.
  14. Bastick E. Drug pipeline developments: alopecia areata and atopic dermatitis. October 6, 2016. www.managedhealthcareexecutive.com/view/drug-pipeline-developments-alopecia-areata-and-atopic-dermatitis. Accessed June 14, 2021.
  15. Pharmaceutical Strategies Group. State of Specialty report. 2020. Plano, TX; PSG.
  16. Starner CI, Alexander GC, Bowen K, Qiu Y, Wickersham PJ, Gleason PP. Specialty drug coupons lower out-of-pocket costs and may improve adherence at the risk of increasing premiums. Health Aff (Millwood). 2014;33(10):1761-1769.